Psilocybin trial misses primary endpoint in treatment-resistant depression

Overview

Updated 1 hour ago

The largest European trial of psilocybin for treatment-resistant depression failed its primary test. In results published this week in JAMA Psychiatry, 17% of patients who received one guided 25-milligram dose met the response threshold at six weeks, versus 10.6% on an active placebo. The gap missed statistical significance.

Secondary analyses showed larger symptom reductions with the high dose, so the trial reads as inconclusive rather than a clean failure. The miss lands at a fragile moment for psychedelic medicine: if a well-run trial cannot beat placebo on its primary measure, regulators have little basis to approve psilocybin. Roughly a third of people with major depression do not respond to standard treatments, leaving few options.

Why it matters

Psilocybin's path to approval for treatment-resistant depression narrows after a rigorous European trial missed its primary endpoint.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

17%

Six-week response rate, 25 mg psilocybin arm

8 of 47 participants met the HAMD17 response threshold (≥50% reduction).

10.6%

Six-week response rate, active placebo

5 of 47 responded to nicotinamide; the comparison missed significance (OR 1.73, P=.19).

144

Participants randomized

Adults ages 25–65 with treatment-resistant depression at two German outpatient centers.

34%

Week 1 response rate, 25 mg arm

16 of 47 responded at one week versus 6.4% for placebo — a clear early effect that faded.

Suicidal ideation on dosing days, 25 mg arm

Versus 1%–2% in comparator conditions; one case of hallucinogen persisting perception disorder was reported.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

EPISODE trial investigators

Research team behind the phase 2b trial

Reported inconclusive primary results in JAMA Psychiatry

Organizations Involved

JAMA Psychiatry

Medical journal

Publisher of the EPISODE trial results

A peer-reviewed psychiatry journal published by the American Medical Association.

Central Institute of Mental Health (ZI Mannheim)

Research institute and psychiatric hospital

Coordinating center for the EPISODE trial

A German psychiatric research institute affiliated with Heidelberg University's medical faculty.

Timeline

November 2025 September 2026

2 events Latest: Today

September 2026
JAMA Psychiatry publishes EPISODE trial results
Today Publication

Primary endpoint missed: 17.0% of the 25 mg arm responded at six weeks versus 10.6% for placebo; secondary analyses favored the high dose.
Today
November 2025
EPISODE trial completes final data analysis
Research

The phase 2b trial's statistical analysis period ended, covering 144 participants at two German centers.
November 30th, 2025

Scenarios

Regulators demand more evidence after EPISODE

Likely Resolves by End of 2027

Discussed by: Regulatory analysts and psychedelic medicine researchers cited in the trial commentary

The FDA or the European Medicines Agency responds to pending psilocybin development programs by requiring additional well-powered confirmatory trials, pointing explicitly to EPISODE's missed primary endpoint. This would push any approval several years out and raise development costs for sponsors.

Psilocybin approved for depression despite the miss

Possible Resolves by End of 2028

Discussed by: Psychedelic drug developers and investor commentators

Sponsors argue the totality of evidence — EPISODE's secondary outcomes, the positive NHS feasibility trial, and earlier phase 2 data — outweighs one negative primary analysis. The FDA approves a psilocybin product for treatment-resistant depression, mirroring esketamine's contested path to market.

Field pivots to repeated-dosing trials

Likely Resolves by End of 2027

Discussed by: Trial investigators quoted in the EPISODE publication and ZI Mannheim press materials

Researchers conclude that one 25 mg session is insufficient, citing EPISODE's fading early benefit and the absence of added effect from a second dose within the study window. A major sponsor registers a phase 3 program testing two or more psilocybin sessions, changing the treatment paradigm.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

February–March 2019

Esketamine (Spravato) approval (2019)

Johnson & Johnson's esketamine nasal spray won FDA approval for treatment-resistant depression in March 2019 — despite its advisory committee voting 14–2 against approval a month earlier on efficacy and safety doubts. The drug reached the market anyway.

Then

Spravato launched as the first new TRD drug in decades, but uptake was slow.

Now

Insurers and clinicians restricted real-world use, and post-marketing evidence remained contested.

Why this matters now

Shows regulators can approve TRD treatments with imperfect data — but payers and clinicians can blunt adoption, shaping what approval would actually mean for psilocybin.

2024

COMPASS Pathways phase 3 failures (2024–2025)

COMPASS Pathways ran the largest clinical program for psilocybin in depression. Its pivotal phase 3 trials failed to meet primary endpoints, and the company later halted development and cut most of its workforce.

Then

COMPASS's market value collapsed and investor enthusiasm for psychedelics cooled sharply.

Now

The field's largest commercial program ended, leaving academic trials like EPISODE as the remaining rigorous evidence base.

Why this matters now

EPISODE is the second major negative readout in the field within two years, compounding doubts about single-dose psilocybin for depression.

2026

NHS psilocybin feasibility trial (2026)

A randomized trial at one National Health Service site in England gave 60 adults with treatment-resistant depression a single 25 mg psilocybin dose or placebo with psychological support. At three weeks, the psilocybin group scored 10.41 points lower on the Montgomery–Åsberg Depression Rating Scale (Cohen's d = −1.70), a difference sustained at six weeks.

Then

The NHS trial reported strong, sustained antidepressant effects favoring psilocybin.

Now

It supports a confirmatory trial in a public healthcare setting, keeping the evidence base genuinely mixed.

Why this matters now

A positive result in a public healthcare setting contrasts sharply with EPISODE's inconclusive primary analysis, showing how much trial design and endpoint choice matter in this field.